Abstract
Soft-tissue sarcomas are mesenchymal tumors that respond poorly to systemic chemotherapy. Suicide gene therapy may be an alternative treatment strategy. Here we show a high susceptibility of human sarcoma cell lines for recombinant adeno-associated virus 2 (rAAV-2) suicide vectors: connective tissue sarcoma (HS-1), fibrosarcoma (HT-1080), Ewing sarcoma (RD-ES), Askin tumor (SK-N-MC), rhabdomyosarcoma (A-204) and soft-tissue sarcoma (WSKL-1). Several vectors containing the thymidine kinase (TK) gene under the control of either the cytomegalovirus promoter or the elongation-factor 1 alpha (EF1α) promoter were cloned and tested. Higher expression levels of the transgene were observed in the sarcoma lines when using the EF1α-suicide gene-containing vectors. A complete eradication of rAAV-2-EF1α-TK/eGFP (TK/enhanced green fluorescent protein fusion gene)-transduced tumor cells was shown following exposure to ganciclovir (2.5 μg/ml) in vitro, while at this dose level >90% of mock-transduced tumor cells survived. Xenotransplantation tumor models (intraperitoneal, subcutaneous) for the human sarcoma cell line HS-1 were established in nonobese diabetic/severe-combined immunodeficient mice. Mice transplanted with rAAV-2-EF1α-TK/eGFP-transduced and ganciclovir-exposed tumor cells survived >5 months while in the nontransduced group all mice had died approximately 1 month after inoculation. These data hold promise for further development of rAAV-2-based suicide gene therapy of sarcomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brennan MF, Casper ES, Harrison LB . Soft-tissue sarcoma. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Ed. 5. Philadelphia, PA: Lippincott-Raven; 1997: 1738–1788.
Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic Soft-tissue sarcomas in adults: a study of the european organization for research and treatment of cancer Soft-tissue and bone sarcoma group. J Clin Oncol. 2000;18:2081–2086.
Hasenburg A, Tong XW, Fischer DC, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol. 2001;83:549–554.
Sung MW, Yeh HC, Thung SN, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther. 2001;4:182–191.
Kanazawa T, Urabe M, Mizukami H, et al. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther. 2001;8:99–106.
Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS . Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport. 2001;12:1961–1964.
Kruse CA, Lamb C, Hogan S, et al. Purified herpes simplex thymidine kinase retroviral particles II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther. 2000;7:118–127.
Carrio M, Mazo A, Lopez-Iglesias C, Estivill X, Fillat C . Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer. 2001;94:81–88.
Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA. 1983;80:2767–2770.
Okada T, Shah M, Higginbotham JN, et al. AV/TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Therapy. 2001;8:1315–1322.
Bantel-Schaal U . Adeno-associated parvoviruses inhibit growth of cells derived from malignant human tumors. Int J Cancer. 1990;45:190–194.
Klein-Bauernschmitt P, von Knebel-Doeberitz M, Ehrbar M, et al. Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells. Eur J Cancer. 1996;32a:1774–1780.
Rosenfeld MR, Bergman I, Schramm L, et al. Adeno-associated viral vector gene transfer into leptomeningeal xenografts. J Neurooncol. 1997;34:139–144.
Maass G, Bogedain C, Scheer U, et al. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther. 1998;9:1049–1059.
Veldwijk MR, Schiedlmeier B, Kleinschmidt JA, et al. Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks. Eur J Cancer. 1999;35:1136–1142.
Veldwijk MR, Fruehauf S, Schiedlmeier B, et al. Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells. Cancer Gene Ther. 2000;7:597–604.
Fillat C, Carrio M, Cascante A, Sangro B . Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13–26.
Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant AAV vectors. Hum Gene Ther. 1998;9:2745–2760.
Zolotukhin S, Potter M, Hauswirth WW, et al. “Humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646–4654.
Salmon P, Kindler V, Ducrey O, et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood. 2000;96:3392–3398.
Steffens S, Frank S, Fischer U, et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther. 2000;7:806–812.
Veldwijk MR, Topaly J, Laufs S, et al. Rapid determination of adeno-associated virus 2 vector titers using an optimized real-time quantitative polymerase chain reaction-based titration assay that meets clinical laboratory standards. Mol Ther. 2002;6:272–278.
Salvetti A, Oreve S, Chadeuf G, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther. 1998;9:695–706.
Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–1423.
Reeves BR, Fisher C, Smith S, et al. Ultrastructural, immunocytochemical, and cytogenetic characterization of a human epithelioid sarcoma cell line (RM-HS1). J Natl Cancer Inst. 1987;78:7–18.
Rasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33:1027–1033.
Biedler JL, Helson L, Spengler BA . Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973;33:2643–2652.
Dunn T, Praissman L, Hagag N, Viola MV . ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet. 1994;76:19–22.
Tamayose K, Hirai Y, Shimada T . A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther. 1996;7:507–513.
Auricchio A, Hildinger M, O'Connor E, et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001;12:71–76.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
Beltinger C, Fulda S, Kammertoens T, et al. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res. 2000;60:3212–3217.
Koshikawa N, Takenaga K, Tagawa M, Sakiyama S . Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000;60:2936–2941.
Miyauchi M, Yoshida Y, Tada Y, et al. Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int J Cancer. 2001;91:723–727.
Rivas C, Miller AR, Collado M, et al. BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. Mol Ther. 2001;3:642–652.
Prochazka M, Gaskins HR, Shultz LD, Leiter EH . The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA. 1992;89:3290–3294.
Kasper B, Fruehauf S, Schiedlmeier B, et al. Xenograft models for normal and malignant human hematopoiesis – possibilities for new treatment strategies. In: Fiebig HH, Burger AM, (Eds.): Relevance of tumor models for anticancer drug development. Basel, Karger, Contrib Oncol. 1999;54:233–248.
Schiedlmeier B, Kuhlcke K, Eckert HG, et al. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood. 2000;95:1237–1248.
Laufs S, Gentner B, Nagy KZ, et al. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood. 2003;101:2191–2198.
Acknowledgements
We are grateful to Sigrid Heil, Hans-Jürgen Engel, Bernhard Berkus and the staff of the German Cancer Research Center animal facility for their technical support (German Cancer Research Center, Heidelberg, Germany). This work was supported in part by a grant of the Joachim-Kuhlmann-Stiftung (Essen, Germany). We are grateful to Dr. J.A. Kleinschmidt (German Cancer Research Center, Heidelberg) for providing the plasmid p.DG and for providing the plasmid PHR-HIV-EF1α. Prof. Dr. D. Trono (University of Geneva)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Veldwijk, M., Berlinghoff, S., Laufs, S. et al. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. Cancer Gene Ther 11, 577–584 (2004). https://doi.org/10.1038/sj.cgt.7700718
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700718
Keywords
This article is cited by
-
Ewing sarcoma treatment: a gene therapy approach
Cancer Gene Therapy (2023)
-
Role of Virus-Directed Therapy in Soft Tissue Sarcoma
Current Treatment Options in Oncology (2022)
-
Normal-Tissue Radioprotection by Overexpression of the Copper-Zinc and Manganese Superoxide Dismutase Genes
Strahlentherapie und Onkologie (2009)
-
Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line
Genetic Vaccines and Therapy (2008)
-
Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury
Nature Reviews Cancer (2007)